Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.
The U.S. Food and Drug Administration announced today that it has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the six manufacturers licensed to produce and distribute influenza vaccine for the United States.
According to an announcement from the Food and Drug Administration (FDA) on Monday, it has approved the new flu vaccine for the season beginning this year. Each year the FDA works with other federal agencies and global health experts to design a vaccine to protect against the three viral strains most likely to cause the flu.
The Influenza Specialist Group (ISG) is today warning that high rates of influenza outbreaks have been confirmed in QLD, SA and NSW, but there is still time for most Australians, especially those in at-risk groups, to protect themselves and those around them.
MedImmune has received confirmation from the U.S. Food & Drug Administration (FDA) that the Agency has filed the Company's supplemental Biologics License Application (sBLA) for a quadrivalent (four-strain) version of FluMist® (Influenza Vaccine Live, Intranasal). The company submitted the sBLA early in the second quarter of this year.
A test, novel breath measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.
A new University of Maryland-led study finds that 'sex' between the virus responsible for the 2009 flu pandemic (H1N1) and a common type of avian flu virus (H9N2) can produce offspring -- new combined flu viruses -- with the potential for creating a new influenza pandemic.
In a large five nation study from Europe it was seen that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barré Syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.
Family doctors are reluctant to disclose identifiable patient information, even in the context of an influenza pandemic, mostly in an effort to protect patient privacy.
A universal flu vaccine, capable of working against all strains, would save lives and money by eliminating the need for the annual jab say experts. Researchers in California and the Netherlands believe they are now a “step closer” to meeting this objective.
Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical company Crucell. They describe an antibody that, in animal tests, can prevent or cure infections with a broad variety of influenza viruses, including seasonal and potentially pandemic strains.
Back in spring 2009, the H1N1 influenza virus crossed the U.S. border and raised concerns that it might cause a full-scale epidemic in the fall. The Food and Drug Administration worked with other Health and Human Services agencies and vaccine manufacturers to quickly develop, license and distribute a vaccine to protect the public from this particularly virulent strain of the flu.
GAO on Monday published two reports on the government's response to the 2009 H1N1 influenza pandemic.
CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.
Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.
CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.
PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Health Canada has approved PURE™ Hard Surface disinfectant for use in food premises, hospitals and health care facilities, domestic locations and institutional and industrial premises.
Infants born to mothers who received the influenza (flu) vaccine while pregnant are nearly 50 percent less likely to be hospitalized for the flu than infants born to mothers who did not receive the vaccine while pregnant, according to a new collaborative study by researchers at Wake Forest Baptist Medical Center and colleagues.
CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.